



Medivation Contacts:

Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Senior Director, Investor Relations
(650) 218-6900

Astellas Contacts:

Jenny Kite
Corporate Communications
(847) 317-5405

Mike Beyer
Sam Brown, Inc (media for both companies)
(773) 463-4211

Medivation and Astellas Announce Enzalutamide (Formerly MDV3100) Data to Be Presented at ASCO Annual Meeting 2012

SAN FRANCISCO, CA AND TOKYO – May 18, 2012 -- Medivation Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. today announced that six abstracts related to enzalutamide (formerly MDV3100) will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL from June 1 -5, 2012.

Details of the abstracts are as follows:

(Abstract #4519): Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor

- Saturday, June 2 from 8:30 a.m. – 8:45 a.m.
Presenter: Johann S. De Bono, MB, ChB, FRCP, MSc, PhD
Clinical Science Symposium: New Paradigms for Hormone Therapy in Prostate Cancer
Location: E Arie Crown Theater

(Abstract #564 / Poster #4G): Effect of MDV3100, an androgen receptor signaling inhibitor, on tumor growth of estrogen and androgen receptor-positive (ER+/AR+) breast cancer xenografts

- Saturday, June 2 from 8:00 a.m. to noon
Author: Anthony D. Elias, MD
General Poster Session: Breast Cancer
Location: S Hall A2

(Abstract #TPS668 / Poster #18B): MDV3100-08: A phase I open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of MDV3100 in women with incurable breast cancer

- Saturday, June 2 from 8:00 a.m. to noon
Author: Anthony D. Elias, MD
General Poster Session: Breast Cancer
Location: S Hall A2

(Abstract #TPS4695 / Poster #16F): A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer

- Sunday, June 3 from 8:00 a.m. to noon
Author: Robert B. Montgomery, MD
General Poster Session: Genitourinary Cancer
Location: S Hall A2

(Abstract #TPS4698 / Poster #17A): TERRAIN: A randomized, double-blind, phase II study comparing MDV3100 with bicalutamide (Bic) in men with metastatic castrate-resistant prostate cancer (CRPC)

- Sunday, June 3 from 8:00 a.m. to noon
Author: Edwina S. Baskin-Bey, MD
General Poster Session: Genitourinary Cancer
Location: S Hall A2

(Abstract #3072 / Poster #16F): Effect of MDV3100, a novel androgen receptor signaling inhibitor, on cell proliferation and tumor size in an apocrine breast cancer xenograft model

- Monday, June 4 from 8:00 A a.m. – noon
Author: Sebastián Bernales, PhD
General Poster Session: Developmental Therapeutics
Location: S Hall A2

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug enzalutamide in Phase 3 development to treat advanced prostate cancer and in Phase 1 development to treat breast cancer. For more information, please visit us at www.medivation.com.

About Astellas Pharma Inc.

Astellas Pharma Inc. is a pharmaceutical company dedicated to improving the health of people around the world through provision of innovative and reliable pharmaceuticals. The organization is committed to becoming a global category leader in Oncology, and has several oncology compounds in development in addition to MDV3100. For more information on Astellas Pharma Inc., please visit our website at www.astellas.com/en.